A single point mutation on FLT3L-Fc protein increases the risk of immunogenicity.

ABSTRACT:

Introduction

As a crucial asset for human health and modern medicine, an increasing number of biotherapeutics are entering the clinic. However, due to their complexity, these drugs have a higher potential to be immunogenic, leading to the generation of anti-drug antibodies (ADAs). Clinically significant ADAs have an impact on pharmacokinetics (PK), pharmacodynamics (PD), effectiveness, and/or safety. Thus, it is crucial to understand, manage and minimize the immunogenicity potential during drug development, ideally starting from the molecule design stage.

Methods

In this study, we utilized various immunogenicity risk assessment methods, including in silico prediction, dendritic cell internalization, MHC-associated peptide proteomics, in vitro HLA peptide bindin

SUBMITTER: Qin D 

PROVIDER: S-EPMC11865242 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature